Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward

Christopher A Green¹, Mohammed N Quraishi², Sahida Shabir³, Naveen Sharma⁴, Richard Hansen⁵, Daniel R Gaya⁶, Ailsa L Hart⁷, Nicholas J Loman⁸, Tariq H Iqbal¹

Affiliations

¹ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
² University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: m.n.quraishi@bham.ac.uk.
³ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK.
⁴ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁵ Department of Paediatric Gastroenterology, Royal Hospital for Children Glasgow, Glasgow, UK.
⁶ Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK.
⁷ Department of Gastroenterology, St Marks Hospital, London, UK.
⁸ Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.

PMID: 32240618
PMCID: PMC7225406
DOI: 10.1016/S2468-1253(20)30089-3

Comment

Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward

Christopher A Green et al. Lancet Gastroenterol Hepatol. 2020 Jun.

. 2020 Jun;5(6):531.

doi: 10.1016/S2468-1253(20)30089-3. Epub 2020 Mar 30.

Authors

Christopher A Green¹, Mohammed N Quraishi², Sahida Shabir³, Naveen Sharma⁴, Richard Hansen⁵, Daniel R Gaya⁶, Ailsa L Hart⁷, Nicholas J Loman⁸, Tariq H Iqbal¹

Affiliations

¹ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
² University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: m.n.quraishi@bham.ac.uk.
³ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK.
⁴ University of Birmingham Microbiome Treatment Centre, Birmingham B15 2TT, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
⁵ Department of Paediatric Gastroenterology, Royal Hospital for Children Glasgow, Glasgow, UK.
⁶ Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK.
⁷ Department of Gastroenterology, St Marks Hospital, London, UK.
⁸ Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.

PMID: 32240618
PMCID: PMC7225406
DOI: 10.1016/S2468-1253(20)30089-3

No abstract available

PubMed Disclaimer

Comment on

Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.
Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota G. Ianiro G, et al. Lancet Gastroenterol Hepatol. 2020 May;5(5):430-432. doi: 10.1016/S2468-1253(20)30082-0. Epub 2020 Mar 17. Lancet Gastroenterol Hepatol. 2020. PMID: 32192627 Free PMC article. No abstract available.

Cited by

Batch Culture Formulation of Live Biotherapeutic Products.
Qiu K, Anselmo AC. Qiu K, et al. Adv Ther (Weinh). 2021 Feb;4(2):2000226. doi: 10.1002/adtp.202000226. Epub 2020 Nov 23. Adv Ther (Weinh). 2021. PMID: 33709021 Free PMC article.
Fecal microbiota transplantation and donor screening for Clostridioides difficile infection during COVID-19 pandemic.
Chiu CH, Tsai MC, Cheng HT, Le PH, Kuo CJ, Chiu CT. Chiu CH, et al. J Formos Med Assoc. 2021 Feb;120(2):791-793. doi: 10.1016/j.jfma.2020.07.028. Epub 2020 Jul 23. J Formos Med Assoc. 2021. PMID: 32713786 Free PMC article. No abstract available.
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study.
Ianiro G, Bibbò S, Masucci L, Quaranta G, Porcari S, Settanni CR, Lopetuso LR, Fantoni M, Sanguinetti M, Gasbarrini A, Cammarota G. Ianiro G, et al. Dig Liver Dis. 2020 Dec;52(12):1390-1395. doi: 10.1016/j.dld.2020.09.004. Epub 2020 Sep 28. Dig Liver Dis. 2020. PMID: 33004295 Free PMC article.
Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease.
Del Barrio M, Lavín L, Santos-Laso Á, Arias-Loste MT, Odriozola A, Rodriguez-Duque JC, Rivas C, Iruzubieta P, Crespo J. Del Barrio M, et al. Int J Mol Sci. 2023 Mar 24;24(7):6123. doi: 10.3390/ijms24076123. Int J Mol Sci. 2023. PMID: 37047094 Free PMC article. Review.
High prevalence of extended-spectrum beta-lactamase organisms and the COVID-19 pandemic impact on donor recruitment for fecal microbiota transplantation in Hong Kong.
Yau YK, Mak WYJ, Lui NSR, Ng WYR, Cheung CYK, Li YLA, Ching YLJ, Chin ML, Lau HSL, Chan KLF, Chan KSP, Ng SC. Yau YK, et al. United European Gastroenterol J. 2021 Nov;9(9):1027-1038. doi: 10.1002/ueg2.12160. Epub 2021 Oct 8. United European Gastroenterol J. 2021. PMID: 34623758 Free PMC article.

See all "Cited by" articles

References

1. Ianiro G, Mullish BH, Kelly CR. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020 doi: 10.1016/S2468-1253(20)30082-0. published online March 17. - DOI - PMC - PubMed
1. European Centre for Disease Prevention and Control Situation update for the EU/EEA and the UK, as of 19 March 2020. March 19, 2020. https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea
1. Xu Y, Li X, Zhu B. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020 doi: 10.1038/s41591-020-0817-4. published online March 13. - DOI - PMC - PubMed
1. Bai Y, Yao L, Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020 doi: 10.1001/jama.2020.2565. published online Feb 21. - DOI - PMC - PubMed
1. US Food and Drug Administration Fecal microbiota for transplantation: safety alert – risk of serious adverse events likely due to transmission of pathogenic organisms. March 12, 2020. https://www.fda.gov/safety/medical-product-safety-information/fecal-micr...

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward

Affiliations

Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous